WRN inhibitor GSK4418959
Term · Oncology and biomedicine · MLC-T-ONC-017570
An orally bioavailable inhibitor of the Werner syndrome ATP-dependent helicase (WRN), with potential antineoplastic activity. Upon oral administration, WRN inhibitor GSK4418959 targets, binds to and inhibits the activity of WRN. This may inhibit the growth of susceptible tumor cells, such as ones with high microsatellite instability (MSI-H). WRN, a multifunctional enzyme with both helicase and exonuclease activities, plays a key role in DNA replication and repair. It is overexpressed in a variety of cancer cells.
| Identifier | MLC-T-ONC-017570 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Werner syndrome ATP-dependent helicase inhibitor GSK4418959; WRNi GSK4418959 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017570",
"term": "WRN inhibitor GSK4418959",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of the Werner syndrome ATP-dependent helicase (WRN), with potential antineoplastic activity. Upon oral administration, WRN inhibitor GSK4418959 targets, binds to and inhibits the activity of WRN. This may inhibit the growth of susceptible tumor cells, such as ones with high microsatellite instability (MSI-H). WRN, a multifunctional enzyme with both helicase and exonuclease activities, plays a key role in DNA replication and repair. It is overexpressed in a variety of cancer cells.",
"synonyms": [
"Werner syndrome ATP-dependent helicase inhibitor GSK4418959",
"WRNi GSK4418959"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/wrn-inhibitor-gsk4418959/"
}
Record 17,454 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.